Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Adv Sci (Weinh) ; 10(7): e2205389, 2023 03.
Article in English | MEDLINE | ID: mdl-36642846

ABSTRACT

Proteins are among the most common therapeutics for the treatment of diabetes, autoimmune diseases, cancer, and metabolic diseases, among others. Despite their common use, current protein therapies, most of which are injectables, have several limitations. Large proteins such as monoclonal antibodies (mAbs) suffer from poor absorption after subcutaneous injections, thus forcing their administration by intravenous injections. Even small proteins such as insulin suffer from slow pharmacokinetics which poses limitations in effective management of diabetes. Here, a deep eutectic-based delivery strategy is used to offer a generalized approach for improving protein absorption after subcutaneous injections. The lead formulation enhances absorption of mAbs after subcutaneous injections by ≈200%. The same composition also improves systemic absorption of subcutaneously injected insulin faster than Humalog, the current gold-standard of rapid acting insulin. Mechanistic studies reveal that the beneficial effect of deep eutectics on subcutaneous absorption is mediated by their ability to reduce the interactions of proteins with the subcutaneous matrix, especially collagen. Studies also confirm that these deep eutectics are safe for subcutaneous injections. Deep eutectic-based formulations described here open new possibilities for subcutaneous injections of therapeutic proteins.


Subject(s)
Biological Products , Deep Eutectic Solvents , Humans , Antibodies, Monoclonal/pharmacokinetics , Deep Eutectic Solvents/pharmacology , Deep Eutectic Solvents/therapeutic use , Diabetes Mellitus/drug therapy , Diabetes Mellitus/therapy , Injections, Subcutaneous/methods , Insulin , Biological Products/administration & dosage , Biological Products/therapeutic use
2.
Adv Sci (Weinh) ; 8(17): e2004819, 2021 09.
Article in English | MEDLINE | ID: mdl-34245140

ABSTRACT

The use of ionic liquids and deep eutectic solvents in biomedical applications has grown dramatically in recent years due to their unique properties and their inherent tunability. This review will introduce ionic liquids and deep eutectics and discuss their biomedical applications, namely solubilization of drugs, creation of active pharmaceutical ingredients, delivery of pharmaceuticals through biological barriers, stabilization of proteins and other nucleic acids, antibacterial agents, and development of new biosensors. Current challenges and future outlooks are discussed, including biocompatibility, the potential impact of the presence of impurities, and the importance of understanding the microscopic interactions in ionic liquids in order to design task-specific solvents.


Subject(s)
Biomedical Technology/methods , Drug Delivery Systems/methods , Ionic Liquids/chemistry , Ionic Liquids/therapeutic use , Pharmaceutical Preparations/chemistry , Biocompatible Materials/chemistry , Biocompatible Materials/therapeutic use , Humans , Ionic Liquids/administration & dosage
3.
Adv Healthc Mater ; 10(13): e2002192, 2021 07.
Article in English | MEDLINE | ID: mdl-34050617

ABSTRACT

The mucus barrier lining the gastrointestinal tract poses a significant barrier to the oral delivery of macromolecular drugs. Successful approaches to overcoming this barrier have primarily focused on reducing drug and carrier interactions with mucus or disrupting the mucus layer directly. Choline-based ionic liquids (ILs) such as choline geranate and choline glycolate (CGLY) have recently been shown to be effective in enhancing the intestinal absorption of macromolecules such as insulin and immunoglobulin (IgG), respectively. Herein, the use of choline-based ILs as mucus-modulating agents for safely improving drug penetration through mucus is described. Choline-based ILs significantly increase the diffusion rates of cationic dextrans through mucin solution. Choline-maleic acid (CMLC 2:1) enhances the diffusion of 4 kDa cationic dextran in mucin solution by more than fourfold when compared to phosphate-buffered saline control. Choline-based ILs also reduce mucus viscosity without significantly impacting the native mucus gel structure. In vitro studies in a mucus-secreting coculture model with Caco-2 and HT29MTX-E12 cells further demonstrate the effectiveness of ILs in improving transport of cationic molecules in the presence of secreted mucus. This work demonstrates the potential for choline-based ionic liquids to be used as nondestructive mucus-modulating agents for enabling enhanced oral delivery of macromolecular drugs.


Subject(s)
Ionic Liquids , Pharmaceutical Preparations , Caco-2 Cells , Drug Delivery Systems , Humans , Mucus
4.
Adv Mater ; 31(27): e1901103, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31112631

ABSTRACT

Ionic liquids (ILs) and deep eutectic solvents have shown great promise in drug delivery applications. Choline-based ILs, in particular choline and geranic acid (CAGE), have been used to enhance the transdermal delivery of several small and large molecules. However, detailed studies outlining the design principles of ILs for transdermal drug delivery are still lacking. Using two model drugs of differing hydrophilicities, acarbose and ruxolitinib and 16 ILs, the dependence of skin penetration on the chemical properties of ILs is examined. First, the impact of ion stoichiometry on skin penetration of drugs is assessed using CAGE, which evidences that a molar ratio of 1:2 of choline to geranic acid yields the highest delivery. Subsequently, variants of CAGE are prepared using anions with structural similarity to geranic acid and cations with structural similarity to choline at a ratio of 1:2. Mechanistic studies reveal that the potency of ILs in enhancing transdermal drug delivery correlates inversely with the inter-ionic interactions as determined by 2D NMR spectroscopy. Using this understanding, a new IL is designed, and it provides the highest delivery of ruxolitinib of all ILs tested here. Overall, these studies provide a generalized framework for optimizing ILs for enhancing skin permeability.


Subject(s)
Acarbose/administration & dosage , Carboxylic Acids/chemistry , Drug Carriers/chemistry , Ionic Liquids/chemistry , Pyrazoles/administration & dosage , Administration, Cutaneous , Animals , Choline/chemistry , Guinea Pigs , Hydrogen-Ion Concentration , Hydrophobic and Hydrophilic Interactions , Nitriles , Permeability , Pyrimidines , Skin/metabolism , Solvents/chemistry , Terpenes/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...